ArticleCureus2025
Hereditary Angioedema With Normal C1 Esterase Inhibitor: A Case of a Late Diagnosis in a 48-Year-Old Male.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hereditary angioedema (HAE) is a rare disorder characterized by recurrent, non-pitting edema affecting the mucosal, submucosal, or subcutaneous tissues. A rarer subtype, HAE with normal C1 esterase inhibitor (HAE-nC1-INH), lacks universally accepted biomarkers. We present a 48-year-old male with a history of Epstein-Barr virus (EBV) and hyperlipidemia, who experienced recurrent episodes of angioedema involving the lips, face, throat, hands, feet, and genitalia. Prior treatments, including corticosteroid injections and oral prednisone, were ineffective. The patient denied any relevant family history and reported symptom exacerbations, potentially triggered by stress. Laboratory evaluation included antinuclear antibody (ANA), C1-INH functional and protein levels, C1Q, total complement, rheumatoid factors, Smith (SM) antibodies, and anti-double-stranded DNA (anti-dsDNA) antibodies. The patient was prescribed icatibant for acute flares and berotralstat for prophylaxis. This case highlights the diagnostic challenges of HAE-nC1-INH, a subtype not responsive to standard treatment with antihistamines or corticosteroids. Although this patient did not experience life-threatening airway compromise, delayed diagnosis of this condition can lead to severe outcomes. Increased awareness of HAE-nC1-INH among clinicians is essential to improve timely diagnosis and appropriate treatment. This case underscores the importance of differentiating HAE-nC1-INH from other forms of angioedema to prevent misdiagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.